This is a clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SXRN Injection in cancer patients with anorexia-cachexia. Phase Ia employs a single-arm, open-label, dose-escalation design. Phase Ib, an extension of the study, utilizes a design of combination therapy with standard anti-tumor therapy for cancers including but not limited to pancreatic cancer, non-small cell lung cancer (NSCLC), and colon cancer.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase Ia: MTD
Timeframe: Up to 90 days post last dosing
Phase Ia&Ib: Incidence of Dose Limiting Toxicities (DLTs)
Timeframe: Up to 21 days after the first dosing of SXRN Injection for each patient
Phase Ib: RP2D
Timeframe: Up to 90 days post last dosing